E. Frenkel

Oncology · Clinical Cancer Research · 2004–2017

A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom E. Frenkel trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. H. Maeda

Who trusts E. Frenkel overall

  1. Stephanie D. Steichen

Papers from E. Frenkel's perspective

Ordered by how strongly the researchers E. Frenkel trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation (Proceedings of the National Academy of Sciences of the United States of America)
  2. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy (Science)
  3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
  4. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota (Science)
  5. Interactions between the microbiota and the immune system (Science)
  6. QIIME allows analysis of high-throughput community sequencing data (Nature Methods)
  7. Metagenomic microbial community profiling using unique clade-specific marker genes
  8. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (The Lancet Oncology)
  9. The microbial metabolites, short chain fatty acids, regulate colonic Treg cell homeostasis (Science)
  10. Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment (Science)

Their papers